Owkin deploys artificial intelligence (AI) and federated learning for medical research and aims to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. It was co-founded in 2016 by Thomas Clozel, a haematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher in New York, New York.